CTOs on the Move

ALung Technologies

www.alung.com

 
ALung Technologies has developed the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis,a simple, less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patients lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million
  • www.alung.com
  • 2500 Jane St Ste 1
    Pittsburgh, PA USA 15203
  • Phone: 412.697.3370

Executives

Name Title Contact Details

Funding

ALung Technologies raised $10.53M on 12/04/2015
ALung Technologies raised $36M on 04/12/2017

Similar Companies

Xtract Solutions

Xtract Solutions is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surgical Technologies

Surgical Technologies is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pacific Bridge Medical

Pacific Bridge Medical is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cordis

With more than a 60-year history of pioneering products to treat millions of patients, Cordis is a worldwide leader in the development and manufacturing of interventional cardiovascular technology. Cordis established a legacy of high-quality and minimally-invasive cardiovascular products; and has built a robust global footprint with operations in more than 60 countries around the world. As from August 2, 2021, Cordis is a standalone company, and is committed to investing $300 million to accelerate innovation in its broad product portfolio. Building on our storied brand, we are unleashing our potential to be a $10 billion leader bringing new technology to the market through bold action at speed.

Bone Biologics

Bone Biologics was founded by University of California Los Angeles professors in collaboration with an Osaka University professor, and a USC surgeon in 2004. Formed to pursue regenerative medicine for bone, the company currently has as its strategic partners the Musculoskeletal Transplant Foundation, the nation's leading tissue bank and Orthofix, a leading global medical device company. Bone Biologics is currently focused on bone regeneration in spinal fusion using its recombinant human protein known as Nell-1. Nell-1 is an osteoinductive orthobiologic; a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.